8-K: Nuvation Bio: Safusidenib Phase 2 Success, IBTROZI Gains

Nuvation Bio reports positive Phase 2 safusidenib results for IDH1-mutant gliomas and strong initial commercial uptake for IBTROZI in ROS1+ NSCLC.

Summary

• Positive results from a Phase 2 study of safusidenib in Japanese patients with chemotherapyand radiotherapy-naive grade 2 IDH1-mutant gliomas were published, meeting its primary endpoint with an objective response rate (ORR) of 44.4%.
• Median progression-free survival (PFS) for safusidenib was not yet reached with a median follow-up time of 28 months, and 87.9% of patients were progression-free at 24 months.
• Adverse events for safusidenib were mostly mild to moderate and manageable, with Grade 3 or greater treatment-related adverse events occurring in 18.5% of patients and no Grade 5 events reported.
• A Good Clinical Practice (GCP) noncompliance issue related to safety reporting was identified during the safusidenib study but was subsequently re-investigated and re-collected to ensure data integrity.
• The G203 study for safusidenib, a global randomized study for maintenance treatment of high-grade IDH1-mutant gliomas, is progressing with a protocol amendment on track to increase sample size and include grade 2 high-risk IDH1-mutant glioma patients, finalizing it as a global Phase 3 study.
• IBTROZI (taletrectinib), a next-generation ROS1 inhibitor, was approved in June 2025 for advanced ROS1+ NSCLC in the U.S., Japan, and China.
• The commercial launch of IBTROZI saw 204 new patient starts in Q3 2025 across the United States.
• Updated median duration of response (DOR) for IBTROZI in TKI-naive patients increased to 50 months as of an August 2025 data cutoff, supporting a planned supplemental New Drug Application (sNDA) by year-end 2025.
• Nuvation Bio maintains a robust cash balance of $549 million as of September 30, 2025, which is expected to provide a path to profitability without the need for additional funding.

Sentiment

Score: 9

Explanation: The filing presents very strong positive clinical data for safusidenib, indicating superior efficacy compared to a competitor, and a successful commercial launch for IBTROZI with updated data showing exceptional durability. The robust cash position and clear path to profitability further enhance the positive sentiment. The only minor negative is a resolved GCP noncompliance issue, which does not significantly detract from the overall positive outlook.

Positives

• Safusidenib's Phase 2 study met its primary endpoint with a 44.4% objective response rate (ORR) in IDH1-mutant grade 2 gliomas.
• Safusidenib demonstrated long-term potential with 87.9% of patients progression-free at 24 months and median progression-free survival (PFS) not reached after 28 months of follow-up.
• The safety profile of safusidenib was favorable, with adverse events being mostly mild to moderate and manageable.
• IBTROZI's commercial launch is off to a strong start, with 204 new patient starts in Q3 2025, indicating rapid market adoption.
• The median duration of response (DOR) for IBTROZI in TKI-naive patients increased to 50 months, reinforcing its potential as a best-in-class therapy with exceptional durability.
• New NCCN Guidelines now include taletrectinib (IBTROZI) as a preferred therapy and specifically contraindicate IO/chemo for ROS1+ NSCLC, providing a significant market advantage.
• The company possesses a robust cash balance of $549 million as of September 30, 2025, which is projected to fund operations to profitability without requiring additional capital raises.
• The pivotal G203 study for safusidenib is expanding to include high-risk, low-grade IDH1-mutant glioma patients, broadening its potential market and impact.
• IBTROZI exhibits high selectivity (1120x) for ROS1 over TRKb, suggesting a differentiated and potentially safer profile compared to other TKIs.
• Two complete responses were observed in high-grade glioma patients treated with safusidenib in a Phase 1 study, highlighting its efficacy in a challenging disease setting.

Negatives

• A Good Clinical Practice (GCP) noncompliance issue regarding the collection of adverse events was identified during the safusidenib Phase 2 study, although it was subsequently resolved through re-investigation to ensure data integrity.

Risks

• Challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to difficulties or delays in the regulatory process, enrolling subjects, or manufacturing or acquiring necessary products.
• The emergence or worsening of adverse events or other undesirable side effects.
• Risks associated with preliminary and interim data, which may not be representative of more mature data.
• Physician and patient behavior.
• Competitive developments in the oncology market.

Future Outlook

Nuvation Bio expects its robust cash balance of $549 million to provide a path to profitability without the need for additional capital. The company plans to file a supplemental New Drug Application (sNDA) for IBTROZI by year-end 2025 based on updated median Duration of Response data. The G203 study for safusidenib is being expanded into a global Phase 3 study to support potential regulatory approvals for high-grade and high-risk low-grade IDH1-mutant gliomas. New data and updates from clinical programs, including taletrectinib and NUV-1511, are anticipated, and discussions to partner IBTROZI in EU and other ex-US territories are ongoing.

Management Comments

• IBTROZI has best-in-class therapeutic potential.
• Safusidenib has the potential to extend its study into high-risk, low-grade patients.
• The robust cash balance of $549 million as of September 30, 2025, is expected to provide a path to profitability without the need for additional funding.
• The launch of IBTROZI is off to a positive start, reinforcing its compelling clinical profile and Nuvation Bio's commercial expertise.
• IBTROZI has the potential to multiply the size of the ROS1+ NSCLC market, similar to precedent growth seen in ALK and EGFR.
• Safusidenib is a potentially best-in-class mIDH1 inhibitor for diffuse IDH1-mutant glioma.
• Drug-drug conjugates (DDCs) are designed to bind two different targets simultaneously.
• NUV-868 is the most BD2-selective BET inhibitor in development.

Industry Context

The oncology market, particularly for non-small cell lung cancer (NSCLC) and glioma, remains highly competitive. IBTROZI's recent approvals and strong initial commercial uptake position it favorably against existing ROS1 TKIs, with Nuvation Bio aiming for a 'best-in-class' profile. The updated NCCN Guidelines, which now prefer taletrectinib and contraindicate IO/chemo for ROS1+ NSCLC, represent a significant market advantage. Safusidenib enters the IDH1-mutant glioma space, where vorasidenib is the only approved IDH1/2 inhibitor for low-grade glioma, highlighting a substantial unmet need, especially for high-grade disease. Nuvation Bio's drug-drug conjugate (DDC) platform represents an innovative approach beyond traditional antibody-drug conjugates (ADCs), potentially opening new therapeutic avenues and addressing diverse cancer types.

Comparison to Industry Standards

• **IBTROZI (Taletrectinib) vs. other ROS1 TKIs (First-line, TKI-naive):** IBTROZI demonstrated a median Duration of Response (DOR) of 50 months (August 2025 data cutoff), significantly higher than Repotrectinib (34 months), Entrectinib (21 months), and Crizotinib (25 months), suggesting superior durability.
• **IBTROZI Safety Profile vs. other ROS1 TKIs:** IBTROZI's 6.5% discontinuation rate due to treatment-emergent adverse events (TEAEs) is the lowest among approved ROS1 TKIs. Its adverse event profile, with ~80% of diarrhea being Grade 1 and >90% of dizziness being Grade 1 and transient, appears more favorable compared to the higher dose modification rates and significant neurological AEs reported for Repotrectinib, Entrectinib, and Crizotinib.
• **Safusidenib vs. Vorasidenib (IDH1-mutant low-grade glioma):** In Phase 2 studies, Safusidenib (J201 study) achieved an 88% 24-month Progression-Free Survival (PFS) rate and a 44% Objective Response Rate (ORR). This compares favorably to Vorasidenib (INDIGO study), which reported a 59% 24-month PFS rate and an 11% ORR, indicating superior efficacy for safusidenib in this patient population.
• **Safusidenib vs. Vorasidenib (IDH1-mutant high-grade glioma):** In Phase 1 studies, Safusidenib demonstrated two complete responses (one in glioblastoma, one in oligodendroglioma) lasting 174 and 95 weeks, respectively, with patients still on treatment. This is a notable outcome in high-grade glioma, a disease with significant unmet needs, and compares favorably to Vorasidenib's reported ORR of 6% in its Phase 1 study for enhancing IDH1/2-mutant gliomas.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong clinical results, successful commercial launch, and robust financial position, potentially leading to increased share value and reduced investment risk.
• **Patients (ROS1+ NSCLC):** Access to a potentially best-in-class treatment (IBTROZI) with superior durability and a favorable safety profile, offering improved outcomes.
• **Patients (IDH1-mutant glioma):** Potential for a new, highly effective treatment (safusidenib) with promising progression-free survival and objective response rates, addressing a significant unmet medical need.
• **Employees:** Positive outlook due to company growth, successful product launches, and strong financial health, potentially leading to job security and opportunities.
• **Regulatory Authorities:** Continued engagement with the U.S. Food and Drug Administration (FDA) and other global regulatory bodies for sNDA and Phase 3 study approvals, ensuring compliance and data integrity.

Next Steps

• File a supplemental New Drug Application (sNDA) for IBTROZI by year-end 2025.
• Progress the G203 study for safusidenib, including a protocol amendment to increase sample size and include grade 2 high-risk IDH1-mutant glioma patients, finalizing it as a global Phase 3 study.
• Share new data and updates from clinical programs, including taletrectinib and NUV-1511.
• Continue discussions to partner IBTROZI in EU and other ex-US territories.
• Evaluate future indications and next steps for the NUV-868 program.

Key Dates

Recommendation

The filing provides compelling evidence of Nuvation Bio's strong pipeline and commercial execution. IBTROZI's exceptional median Duration of Response of 50 months and successful initial launch, coupled with NCCN guideline inclusion, suggest significant market penetration and revenue potential. Safusidenib's Phase 2 results, demonstrating superior PFS and ORR compared to an approved competitor in low-grade glioma and promising complete responses in high-grade disease, position it as a potential best-in-class asset with a large market opportunity. The company's robust cash balance of $549 million, providing a path to profitability without further dilution, significantly de-risks the investment. These factors collectively indicate a strong growth trajectory and potential undervaluation, warranting a 'strong buy' recommendation.

Keywords

Nuvation Bio, NUVB, safusidenib, IBTROZI, taletrectinib, IDH1-mutant glioma, ROS1+ NSCLC, non-small cell lung cancer, oncology, clinical trial, Phase 2, Phase 3, FDA approval, drug development, corporate presentation, financial results, cash balance, DDC, NUV-1511, BET inhibitor, NUV-868, cancer treatment, biopharmaceutical